X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6953) 6953
Book Review (995) 995
Publication (674) 674
Newsletter (102) 102
Book Chapter (17) 17
Conference Proceeding (12) 12
Book / eBook (7) 7
Dissertation (4) 4
Government Document (3) 3
Magazine Article (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6465) 6465
humans (4805) 4805
male (3173) 3173
animals (3010) 3010
pyridines - pharmacokinetics (2486) 2486
pyridines - pharmacology (2368) 2368
female (2105) 2105
pharmacology & pharmacy (2080) 2080
pyridines - therapeutic use (1728) 1728
rats (1463) 1463
pyridines - administration & dosage (1433) 1433
adult (1424) 1424
middle aged (1269) 1269
mice (1109) 1109
pyridines - adverse effects (1083) 1083
pyridines - chemistry (969) 969
pharmacokinetics (966) 966
dose-response relationship, drug (937) 937
aged (900) 900
oncology (885) 885
chemistry, medicinal (822) 822
administration, oral (807) 807
analysis (677) 677
cancer (666) 666
pyridine (664) 664
pyridines - blood (630) 630
structure-activity relationship (625) 625
treatment outcome (589) 589
neurosciences (536) 536
rats, sprague-dawley (536) 536
pyridines - chemical synthesis (503) 503
drug interactions (492) 492
chemistry, organic (455) 455
research (446) 446
pyridines - metabolism (445) 445
drug therapy (444) 444
pharmacology (429) 429
biochemistry & molecular biology (423) 423
pharmacology/toxicology (413) 413
care and treatment (405) 405
medicine & public health (398) 398
niacinamide - analogs & derivatives (398) 398
antineoplastic agents - therapeutic use (395) 395
molecular structure (384) 384
brain - metabolism (382) 382
phenylurea compounds (367) 367
time factors (365) 365
atazanavir sulfate (348) 348
double-blind method (346) 346
cell line, tumor (344) 344
tissue distribution (338) 338
article (337) 337
in-vitro (334) 334
antineoplastic agents - pharmacology (331) 331
biological availability (324) 324
half-life (320) 320
hiv infections - drug therapy (319) 319
safety (313) 313
area under curve (312) 312
dogs (311) 311
young adult (309) 309
toxicology (304) 304
abridged index medicus (302) 302
disease models, animal (301) 301
drug administration schedule (296) 296
health aspects (292) 292
clinical trials as topic (282) 282
therapy (282) 282
kinetics (280) 280
metabolism (280) 280
chemotherapy (279) 279
aged, 80 and over (275) 275
dabigatran (271) 271
adolescent (267) 267
protein kinase inhibitors - therapeutic use (265) 265
rats, wistar (261) 261
sorafenib (260) 260
drugs (259) 259
clinical trials (258) 258
drug therapy, combination (253) 253
imidazoles - pharmacology (251) 251
pyridines (250) 250
protein kinase inhibitors - pharmacology (249) 249
drug design (248) 248
expression (244) 244
in vitro techniques (242) 242
neoplasms - drug therapy (242) 242
brain (238) 238
efficacy (238) 238
zolpidem (235) 235
antineoplastic agents - pharmacokinetics (234) 234
enzyme inhibitors - pharmacology (234) 234
in-vivo (233) 233
protein binding (231) 231
psychiatry (229) 229
double-blind (227) 227
dosage and administration (223) 223
ligands (223) 223
internal medicine (221) 221
chromatography, high pressure liquid (220) 220
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6971) 6971
German (37) 37
French (19) 19
Japanese (19) 19
Spanish (13) 13
Russian (11) 11
Chinese (7) 7
Danish (3) 3
Italian (3) 3
Dutch (2) 2
Norwegian (2) 2
Czech (1) 1
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 9/2011, Volume 50, Issue 9, pp. 551 - 603
Journal Article
AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy | Index Medicus | AIDS/HIV
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2015, Volume 55, Issue 9, pp. 1012 - 1023
Cabozantinib is a small-molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with progressive, metastatic medullary thyroid... 
pharmacokinetics | CYP2C8 | drug–drug interaction | CYP3A4 | cabozantinib | drug-drug interaction | XL184 | ERYTHROMYCIN | SUNITINIB | PHARMACOLOGY & PHARMACY | SORAFENIB | 6-BETA-HYDROXYCORTISOL | Rifampin - pharmacokinetics | Area Under Curve | Ketoconazole - administration & dosage | Humans | Microsomes, Liver - metabolism | Half-Life | Pyridines - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Anilides - pharmacokinetics | Antineoplastic Agents - administration & dosage | Thiazolidinediones - pharmacokinetics | Hypoglycemic Agents - blood | Drug Interactions | Cytochrome P-450 CYP3A Inducers - pharmacokinetics | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacokinetics | Microsomes, Liver - enzymology | Cytochrome P-450 CYP2C8 - metabolism | Rifampin - administration & dosage | Hypoglycemic Agents - pharmacokinetics | Pyridines - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - blood | Ketoconazole - pharmacokinetics | Anilides - blood | Cytochrome P-450 CYP3A Inducers - administration & dosage | Pyridines - blood | Anilides - administration & dosage | Antineoplastic Agents - blood | Thiazolidinediones - blood | Dosage and administration | Ketoconazole | Pharmacokinetics | Rifampin | Analysis | Drug interactions | Plasma | Index Medicus
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2008, Volume 47, Issue 1, pp. 47 - 59
Objectives: To investigate the pharmacokinetic and pharmacodynamic profile of dabigatran in healthy elderly subjects; to assess the intra- and interindividual... 
Dabigatran etexilate | Thrombin inhibitors | Elderly | Research and development | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Dabigatran etexilate, pharmacokinetics | Thrombin inhibitors, pharmacokinetics | REPLACEMENT | APTT | MANAGEMENT | THERAPY | VENOUS THROMBOEMBOLISM | TOTAL HIP | DISEASE | ETEXILATE | PHARMACOLOGY & PHARMACY | Anticoagulants - administration & dosage | Area Under Curve | Humans | Thrombin - antagonists & inhibitors | Pyridines - pharmacokinetics | Biological Availability | Male | Dabigatran | Flatulence - chemically induced | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Diarrhea - chemically induced | Tandem Mass Spectrometry | Hematoma - chemically induced | Capsules | Benzimidazoles - administration & dosage | Aged, 80 and over | Chromatography, Liquid | Anti-Ulcer Agents - pharmacology | Female | Benzimidazoles - blood | Pyridines - administration & dosage | Administration, Oral | Benzimidazoles - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Anticoagulants - blood | Pyridines - blood | Blood Coagulation - drug effects | Partial Thromboplastin Time | Sex Factors | Aged | Anticoagulants - pharmacokinetics | Metabolic Clearance Rate - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Index Medicus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 3/2013, Volume 56, Issue 5, pp. 718 - 726
Background. Boceprevir represents a new treatment option for hepatitis C (HCV)—infected patients, including those with HCV/human immunodeficiency virus... 
HIV/AIDS | HIV | Protease inhibitors | Geometric mean | Memory interference | Drug interactions | Infections | Sample mean | Pharmacokinetics | Dosage | Hepacivirus | pharmacokinetics | darunavir | boceprevir | lopinavir | atazanavir | INFECTIOUS DISEASES | PLUS RIBAVIRIN | DRUG-INTERACTIONS | MICROBIOLOGY | IMMUNOLOGY | OATP1B1 | CYP3A | INTERFERON | COCKTAIL | CYTOCHROME-P450 ENZYMES | GENOTYPE 1 INFECTION | Hepacivirus - drug effects | Darunavir | Proline - analogs & derivatives | Area Under Curve | HIV-1 - drug effects | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Oligopeptides - pharmacokinetics | Pyridines - pharmacokinetics | Male | Sulfonamides - pharmacokinetics | Lopinavir - pharmacokinetics | Proline - pharmacokinetics | Dose-Response Relationship, Drug | Young Adult | Drug Interactions | Ritonavir - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Atazanavir Sulfate | Adult | Female | Boceprevir | Pharmacology, Experimental | Atazanavir | Lopinavir | Dosage and administration | Drug therapy, Combination | Hepatitis C virus | Drug therapy | Health aspects | Clinical trials | Hepatitis | Prescription drugs | Pharmacology | Human immunodeficiency virus--HIV | Index Medicus | All-terrain vehicles | Antiviral agents | Side effects | Ritonavir | Drug interaction | Proteinase inhibitors | Hepatitis C
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2/2011, Volume 67, Issue 2, pp. 393 - 400
The purpose of this study was to develop a population pharmacokinetic (PK) model for 3-AP, to evaluate the effect of ABCB1 polymorphisms on the pharmacokinetic... 
Population pharmacokinetics | 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone | Medicine & Public Health | Triapine | Oncology | Cancer Research | Phase 1 | Pharmacology/Toxicology | 3-aminopyridine-2-carboxaldehyde thiosemicarbazone | ADVANCED SOLID TUMORS | COMBINATION | BLOOD MONONUCLEAR-CELLS | GEMCITABINE | TRIAL | CONSORTIUM | Triapine (R) | ONCOLOGY | RIBONUCLEOTIDE REDUCTASE INHIBITOR | PHARMACOLOGY & PHARMACY | PHASE-I | CARCINOMA | 3-AP | Neoplasms - metabolism | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Metabolic Clearance Rate | Thiosemicarbazones - administration & dosage | Blood - metabolism | Computer Simulation | Aged, 80 and over | Adult | Female | Body Surface Area | Pyridines - administration & dosage | Genotype | Models, Statistical | Sex Characteristics | Neoplasms - drug therapy | Thiosemicarbazones - blood | Thiosemicarbazones - pharmacokinetics | Pyridines - blood | Pyridines - metabolism | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Models, Biological | Erythrocytes - metabolism | Thiosemicarbazones - metabolism | ATP Binding Cassette Transporter, Sub-Family B | Aged | Clinical Trials, Phase I as Topic | Antimitotic agents | Medical colleges | Cancer patients | Care and treatment | Oncology, Experimental | Pharmacy | Research | Antineoplastic agents | Public health | Cancer | Index Medicus | phase 1 | population pharmacokinetics
Journal Article
Molecules, ISSN 1420-3049, 09/2017, Volume 22, Issue 9, p. 1488
Journal Article